Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 8-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Clinical Diagnostics | | 1,305.2 | 1,412.0 | 1,411.8 | 1,360.8 | 1,323.3 | 1,310.4 | 1,432.3 |
| Life Science | | 1,231.8 | 885.9 | 861.7 | 785.2 | 730.7 | 695.0 | 728.3 |
| Other | | 8.6 | 13.8 | 15.9 | 14.2 | 14.2 | 14.0 | 14.4 |
| Total revenues | 2,922.5 | 2,545.6 | 2,311.7 | 2,289.4 | 2,160.2 | 2,068.2 | 2,019.4 | 2,175.0 |
| Revenue growth [+] | 14.8% | 10.1% | 1.0% | 6.0% | 4.4% | 2.4% | -7.2% | 2.0% |
| Clinical Diagnostics | | -7.6% | 0.0% | 3.7% | 2.8% | 1.0% | -8.5% | 1.7% |
| Life Science | | 39.0% | 2.8% | 9.7% | 7.5% | 5.1% | -4.6% | 2.6% |
| Asia | | 8.2% | 1.9% | 7.4% | | | | |
| Cost of goods sold | 1,281.9 | 1,107.8 | 1,054.7 | 1,066.3 | 972.5 | 930.1 | 897.8 | 996.5 |
| Gross profit | 1,640.7 | 1,437.8 | 1,257.0 | 1,223.1 | 1,187.8 | 1,138.1 | 1,121.6 | 1,178.5 |
| Gross margin | 56.1% | 56.5% | 54.4% | 53.4% | 55.0% | 55.0% | 55.5% | 54.2% |
| Selling, general and administrative | 879.6 | 800.3 | 824.6 | 834.8 | 806.8 | 816.7 | 762.0 | 808.2 |
| Research and development | 271.7 | 226.6 | 202.7 | 199.2 | 250.2 | 205.9 | 193.0 | 220.3 |
| Other operating expenses | | -37.1 | -40.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA [+] | | 549.1 | 363.9 | 327.3 | 279.5 | 258.4 | 298.5 | 299.9 |
| EBITDA growth | -10.9% | 50.9% | 11.2% | 17.1% | 8.1% | -13.4% | -0.5% | -5.3% |
| EBITDA margin | 16.7% | 21.6% | 15.7% | 14.3% | 12.9% | 12.5% | 14.8% | 13.8% |
| Depreciation | | 110.6 | 110.7 | 109.8 | 117.9 | 107.7 | 95.3 | 102.1 |
| EBITA | 489.4 | 438.5 | 253.2 | 217.5 | 161.6 | 150.7 | 203.2 | 197.8 |
| EBITA margin | 16.7% | 17.2% | 11.0% | 9.5% | 7.5% | 7.3% | 10.1% | 9.1% |
| Amortization of intangibles | | 27.5 | 23.5 | 28.3 | 30.8 | 35.2 | 36.5 | 47.8 |
| EBIT [+] | 489.4 | 411.0 | 229.7 | 189.2 | 130.8 | 115.5 | 166.7 | 150.0 |
| EBIT growth | 19.1% | 78.9% | 21.4% | 44.7% | 13.2% | -30.7% | 11.2% | -11.5% |
| EBIT margin | 16.7% | 16.1% | 9.9% | 8.3% | 6.1% | 5.6% | 8.3% | 6.9% |
| Non-recurring items [+] | | | | 292.5 | 11.5 | 62.3 | | |
| Asset impairment | | | | 292.5 | 11.5 | 62.3 | | |
| Interest expense | 1.6 | 21.9 | 23.4 | 24.0 | 23.0 | 21.9 | 21.7 | 22.1 |
| Interest expense | 1.6 | 21.9 | 23.4 | 24.0 | 23.0 | 21.9 | 21.7 | 22.1 |
| Other income (expense), net [+] | 4,950.3 | 4,518.5 | 2,054.8 | 640.0 | 1.6 | 10.3 | 0.8 | 3.7 |
| Gain (loss) on foreign currency transactions | | 1.8 | 2.2 | 2.9 | 9.1 | 4.5 | 10.2 | 9.3 |
| Other | 26.8 | 24.5 | 26.1 | 36.6 | 10.7 | 14.9 | 11.1 | 13.0 |
| Pre-tax income | 5,438.1 | 4,907.6 | 2,261.1 | 512.7 | 97.8 | 41.6 | 145.8 | 131.6 |
| Income taxes | 1,192.2 | 1,101.4 | 502.4 | 147.0 | -24.4 | 13.4 | 32.8 | 42.7 |
| Tax rate | 21.9% | 22.4% | 22.2% | 28.7% | | 32.3% | 22.5% | 32.5% |
| Net income | 4,245.9 | 3,806.3 | 1,758.7 | 365.6 | 122.2 | 28.1 | 113.1 | 88.8 |
| Net margin | 145.3% | 149.5% | 76.1% | 16.0% | 5.7% | 1.4% | 5.6% | 4.1% |
| |
| Basic EPS [+] | $142.33 | $127.86 | $58.93 | $12.25 | $4.12 | $0.96 | $3.87 | $3.08 |
| Growth | 11.3% | 117.0% | 380.9% | 197.3% | 331.5% | -75.3% | 25.9% | 13.1% |
| Diluted EPS [+] | $140.56 | $126.20 | $58.27 | $12.10 | $4.07 | $0.95 | $3.85 | $3.05 |
| Growth | 11.4% | 116.6% | 381.7% | 197.2% | 329.0% | -75.3% | 26.1% | 13.3% |
| |
| Shares outstanding (basic) [+] | 29.8 | 29.8 | 29.8 | 29.8 | 29.7 | 29.4 | 29.2 | 28.9 |
| Growth | 0.2% | -0.3% | 0.0% | 0.6% | 0.7% | 0.9% | 1.1% | 1.0% |
| Shares outstanding (diluted) [+] | 30.2 | 30.2 | 30.2 | 30.2 | 30.0 | 29.6 | 29.4 | 29.1 |
| Growth | 0.2% | -0.1% | -0.1% | 0.6% | 1.3% | 0.8% | 0.9% | 0.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|